• Prescribing Information
  • Patient Information
  • Patient Site
  • Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    EUCRISA Safety Data

    Safety profile established in 4 studies, including pivotal and open-label safety extension studies, and an open-label infant safety study

    EUCRISA safety data for the 4-week pivotal trials*,1,2

    See Pivotal Trials Study design

    PIVOTAL TRIALS ADVERSE REACTIONS IN ≥1% PATIENTS

    EUCRISA (n=1012)

    Vehicle (n=499)

    APPLICATION SITE PAIN1
    Refers to skin sensations such as burning or stinging

    4% (n=45)

    1% (n=6)

    • Application site pain resolved within 1 day for 77.6% of patients reporting it3
    • Discontinuation rates due to adverse events were 1.2% for both EUCRISA and vehicle in a pooled analysis3

    APPLICATION SITE PAIN1
    Refers to skin sensations such as burning or stinging

    EUCRISA (n=1012)

    4% (n=45)

    Vehicle (n=499)

    1% (n=6)

    • Application site pain resolved within 1 day for 77.6% of patients reporting it3
    • Discontinuation rates due to adverse events were 1.2% for both EUCRISA and vehicle in a pooled analysis3
    *This pooled data reflects information from Trial 1 and Trial 2 of the pivotal trials where patients enrolled were 2 years and older

    EUCRISA safety data for patients enrolled in the Open-Label Safety Extension study1,4

    See Open-Label Safety Extension study design

    TREATMENT-RELATED ADVERSE EVENTS OCCURRING IN ≥1% OF PATIENTS IN THE OPEN LABEL SAFETY EXTENSION STUDY

    EUCRISA (n=517)

    APPLICATION SITE PAIN2
    Refers to skin sensations such as burning or stinging

    2% (n=12)

    APPLICATION SITE INFECTION2

    1% (n=6)

    ATOPIC DERMATITIS2

    3% (n=16)

     
    • In the Open-Label Safety Extension Study:
      • There were no reports of application site cutaneous adverse reactions of atrophy or telangiectasia4†‡
      • Discontinuation rate due to adverse events was 1.7% for EUCRISA3
      • Seven treatment-emergent SAEs occurred in the open-label safety extension study, but none were considered related to treatment4

    ​​​​​​​SAE=serious adverse event
     

    EUCRISA (n=517)

    APPLICATION SITE PAIN2
    Refers to skin sensations such as burning or stinging

    2% (n=12)

    APPLICATION SITE INFECTION2

    1% (n=6)

    ATOPIC DERMATITIS2

    3% (n=16)

    • In the Open-Label Safety Extension Study:
      • There were no reports of application site cutaneous adverse reactions of atrophy or telangiectasia4†‡
      • Discontinuation rate due to adverse events was 1.7% for EUCRISA3
      • Seven treatment-emergent SAEs occurred in the open-label safety extension study, but none were considered related to treatment4

    ​​​​​​​SAE=serious adverse event​​​​​​​
    Patients enrolled in the open label safety extension study were enrolled following the pivotal trial and were followed for 48 weeks. The total period followed was 52 weeks.​​​​​​​

    ​​​​​​​*This pooled data reflects information from Trial 1 and Trial 2 of the pivotal trials where patients enrolled were 2 years and older
    As per verbatim terms coded using the Medical Dictionary for Regulatory Activities (MedDRA) by System Organ Class/Preferred Term.
    One treatment-emergent adverse event of skin striae at application site was reported (possibly related to study drug).
    References
    1. EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
    2. Data on File. Pfizer Inc., New York, NY.
    3. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
    4. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
    ​​​​​​​
    Not an actual patient

    Watch JP's story

    ** This is an optional area where footnotes can live.

    Rescue Therapy Endpoint

    Read about rescue therapy in the 48 week Open-Label Safety Extension study

    Learn more

    ** This is an optional area where footnotes can live.

    Exploratory Pruritus Endpoint

    Find out more about the time to relief in pruritus as found in the Phase III study's exploratory endpoint

    Learn more

    ** This is an optional area where footnotes can live.

    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    ** This is an optional area where footnotes can live.

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.